NCT04708821View on ClinicalTrials.gov

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

September 2, 2021

Study Completion Date

September 2, 2021

Conditions
Bilateral Conjunctivitis (Disorder)
Interventions
DRUG

Dexamethasone ophthalmic insert 0.4Mg

Dextenza 0.4Mg Ophthalmic Insert

DRUG

0.2% loteprednol etabonate ophthalmic suspension

0.2% loteprednol etabonate ophthalmic suspension

DRUG

olopatadine hydrochloride ophthalmic solution 0.7%

olopatadine hydrochloride ophthalmic solution 0.7%

Trial Locations (1)

33060

Clinical Research Center of Florida, Pompano Beach

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Clinical Research Center of Florida

OTHER